My research focuses on brain-body connections involved in human health and performance. My goal is to understand differences in resiliency, growth and rehabilitation by investigating the pathways and mechanistic drivers that shape physiological, cognitive, and clinical presentations. In this way, I use patient data and computational strategies to dissect complex physical and mental health problems, to discover critical insights for risk classification and personalized care. As a postdoctoral fellow, I have taken this approach to study genetic, cardiovascular and inflammatory influences on the cognitive performance of older adults, and collaborated on multi-modal exercise and cognitive training trails to promote fitness and memory. This research aligns with my clinical training as a rehabilitation psychologist, with the goal of maximizing functional outcomes of my patients.

Stanford Advisors

Research Interests

  • Brain and Learning Sciences
  • Psychology

All Publications

  • BDNF Val66Met Moderates the Effects of Hypertension on Executive Functioning in Older Adults Diagnosed With aMCI. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry Louras, P., Brown, L. M., Gomez, R., Warren, S. L., Fairchild, J. K. 2022


    OBJECTIVE: To investigate whether the BDNF Val66Met polymorphism influences the associations of hypertension, executive functioning and processing speed in older adults diagnosed with amnestic Mild Cognitive Impairment (aMCI).DESIGN: Secondary data analysis using moderation modeling.SETTING: Veterans Affairs Hospital, Palo Alto, CA.PARTICIPANTS: Sample included 108 community-dwelling volunteers (mean age 71.3 ± 9.2 years) diagnosed with aMCI.MEASUREMENTS: Cognitive performance was evaluated from multiple baseline assessments (Trail Making Test; Stroop Color-Word Test; Symbol Digit Modality Test) and grouped into standardized composite scores representing executive function and processing speed domains. BDNF genotypes were determined from whole blood samples. Hypertension was assessed from resting blood pressures or by self-report.RESULTS: Controlling for age, BDNF Val66Met moderated the effects of hypertension on executive functioning, but added no significant variance to processing speed scores. Specifically, hypertensive carriers of the BDNF Met allele performed significantly below the sample mean on tasks of executive functioning, and evidenced significantly lower scores when compared to Val-Val homozygotes and normotensive participants.CONCLUSIONS: Results posit that the executive functioning of non-demented older adults may be susceptible to interactions between BDNF genotype and hypertension, and Val-Val homozygotes and normotensive older adults may be more resilient to these effects of cognitive change. Further research is needed to understand the underlying processes and to implement strategies that target modifiable risk factors and promote cognitive resilience.

    View details for DOI 10.1016/j.jagp.2022.05.012

    View details for PubMedID 35779988

  • Physical Activity "I Can Only Go About a Block Before Running Out of Breath" PRACTICAL STRATEGIES IN GERIATRIC MENTAL HEALTH: CASES AND APPROACHES Fairchild, J., Phillipps, K., Louras, P., Dunn, L. B., CassidyEagle, E. L. 2020: 341-361
  • Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor- Dependent Shock: A Propensity Score- Matched Analysis From 130 US Hospitals CLINICAL INFECTIOUS DISEASES Kadri, S. S., Swihart, B. J., Bonne, S. L., Hohmann, S. F., Hennessy, L. V., Louras, P., Evans, H. L., Rhee, C., Suffredini, A. F., Hooper, D. C., Follmann, D. A., Bulger, E. M., Danner, R. L. 2017; 64 (7): 877-885


    Shock frequently complicates necrotizing fasciitis (NF) caused by group A Streptococcus (GAS) or Staphylococcus aureus. Intravenous immunoglobulin (IVIG) is sometimes administered for presumptive toxic shock syndrome (TSS), but its frequency of use and efficacy are unclear.Adult patients with NF and vasopressor-dependent shock undergoing surgical debridement from 2010 to 2014 were identified at 130 US hospitals. IVIG cases were propensity-matched and risk-adjusted. The primary outcome was in-hospital mortality and the secondary outcome was median length of stay (LOS).Of 4127 cases of debrided NF with shock at 121 centers, only 164 patients (4%) at 61 centers received IVIG. IVIG subjects were younger with lower comorbidity indices, but higher illness severity. Clindamycin and vasopressor intensity were higher among IVIG cases, as was coding for TSS and GAS. In-hospital mortality did not differ between matched IVIG and non-IVIG groups (crude mortality, 27.3% vs 23.6%; adjusted odds ratio, 1.00 [95% confidence interval, .55-1.83]; P = .99). Early IVIG (≤2 days) did not alter this effect (P = .99). Among patients coded for TSS, GAS, and/or S. aureus, IVIG use was still unusual (59/868 [6.8%]) and lacked benefit (P = .63). Median LOS was similar between IVIG and non-IVIG groups (26 [13-49] vs 26 [11-43]; P = .84). Positive predictive values for identifying true NF and debridement among IVIG cases using our algorithms were 97% and 89%, respectively, based on records review at 4 hospitals.Adjunctive IVIG was administered infrequently in NF with shock and had no apparent impact on mortality or hospital LOS beyond that achieved with debridement and antibiotics.

    View details for DOI 10.1093/cid/ciw871

    View details for Web of Science ID 000397439600012

    View details for PubMedID 28034881

    View details for PubMedCentralID PMC5850528